< Back to all clusters
[BUSINESS] · Italy, United States · 6 sources

started · updated

Inta seeks international investment for medical diagnostic technology

Inta, an Italian biotechnology spin-off founded in 2020, is seeking international investment to support its global growth and navigate complex regulatory landscapes. CEO and co-founder Matteo Agostini emphasized the necessity of 'patient capital' to bring medical innovations to market, noting that regulatory processes in Europe and the United States are both time-consuming and capital-intensive.

The company develops Nano Analyzer, a hardware and software tool that utilizes nanotechnology, biotechnology, and artificial intelligence to identify biological markers in liquids. This technology allows for rapid diagnostics without the need for hospital laboratory analysis. A primary application currently under development is the rapid diagnosis of traumatic brain damage through blood analysis, which can be performed in hospital triage areas, ambulances, or helicopters.

Entities

CNR Institute of Nanoscience · INTA · Matteo Agostini · Nano Analyzer · Scuola Normale Superiore

Claims

What the coverage asserts, and how many sources carry each claim.